伴有脂肪肝的遗传代谢性肝病诊断策略*

doi:10.3969/j.issn.1672-5069.2026.04.001

实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (4): 481-484.doi: 10.3969/j.issn.1672-5069.2026.04.001

• 专家论坛 • 下一篇

伴有脂肪肝的遗传代谢性肝病诊断策略^*

吴芃萱, 刘晖, 郑素军

100069 北京市首都医科大学附属北京佑安医院肝病中心一科(吴芃萱,郑素军);病理科(刘晖)

收稿日期:2025-05-28 出版日期:2026-07-10 发布日期:2026-07-20
通讯作者: 郑素军,E-mail:zhengsujun@ccmu.edu.cn
作者简介:吴芃萱,女,24岁,硕士研究生。E-mail:pengxuanwmx@163.com
基金资助:
^*首都卫生发展科研专项重点攻关项目(编号:2022-1-2182);北京市科技新星计划交叉合作项目(编号:20230484455);北京市卫生健康委员会高层次公共卫生技术人才学科带头人培养项目(编号:学科带头人-02-14);北京市医院管理中心“登峰”计划项目(编号:DFL20241701)

Inherited metabolic liver diseases that may present with hepatic steatosis: current state of the art

Wu Pengxuan, Liu Hui, Zheng Sujun

Section One, Liver Disease Center, You’An Hospital, Capital Medical University, Beijing 100069, China

Received:2025-05-28 Online:2026-07-10 Published:2026-07-20

摘要/Abstract

关键词: 遗传代谢性肝病, 脂肪肝, 诊断

Key words: Inherited metabolic liver disease, Liver steatosis, Diagnosis

吴芃萱, 刘晖, 郑素军. 伴有脂肪肝的遗传代谢性肝病诊断策略^*[J]. 实用肝脏病杂志, 2026, 29(4): 481-484.

Wu Pengxuan, Liu Hui, Zheng Sujun. Inherited metabolic liver diseases that may present with hepatic steatosis: current state of the art[J]. Journal of Practical Hepatology, 2026, 29(4): 481-484.

[1] Guindi M. Wilson disease. Semin Diagn Pathol,2019,36(6):415-422.
[2] Schilsky ML. Wilsondisease: diagnosis, treatment, and follow-up. Clin Liver Dis,2017,21(4):755-767.
[3] Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers,2018,4(1):21.
[4] Liggi M, Murgia D, Civolani A, et al. The relationship between copper and steatosis in Wilson's disease. Clin Res Hepatol Gastroenterol,2013,37(1):36-40.
[5] Muchenditsi A, Yang H, Hamilton JP, et al. Targeted inactivation of copper transporter Atp7b in hepatocytes causes liver steatosis and obesity in mice. Am J Physiol Gastrointest Liver Physiol,2017,313(1):G39-G49.
[6] Buziau AM, Schalkwijk CG, Stehouwer CDA, et al. Recent advances in the pathogenesis of hereditary fructose intolerance: implications for its treatment and the understanding of fructose-induced non-alcoholic fatty liver disease. Cell Mol Life Sci,2020,77(9):1709-1719.
[7] Demirbas D, Coelho AI, Rubio-Gozalbo ME, et al. Hereditary galactosemia. Metabolism,2018,83:188-196.
[8] Massese M, Tagliaferri F, Dionisi-Vici C, et al. Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI.Orphanet J Rare Dis,2022,17(1):241.
[9] Wright TLF, Umaña LA, Ramirez CM. Update on glycogen storage disease: primary hepatic involvement. Curr Opin Pediatr,2022,34(5):496-502.
[10] Derks TG, Van Rijn M. Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions.J Inherit Metab Dis,2015,38(3):537-543.
[11] Derks TG, Smit GP. Dietary management in glycogen storage disease type III: what is the evidence? J Inherit Metab Dis,2015,38(3):545-550.
[12] Li H, Byers HM, Diaz-Kuan A, et al. Acute liver failure in neonates with undiagnosed hereditary fructose intolerance due to exposure from widely available infant formulas.Mol Genet Metab,2018,123(4):428-432.
[13] Aldámiz-Echevarría L, De Las Heras J, Couce M, et al. Non-alcoholic fatty liver in hereditary fructose intolerance.Clin Nutr,2020,39(2):455-459.
[14] Tran C. Inbornerrors of fructose metabolism. What can we learn from them? Nutrients,2017,9(4):356.
[15] Merritt JL 2nd, MacLeod E, Jurecka A, et al. Clinical manifestations and management of fatty acid oxidation disorders.Rev Endocr Metab Disord,2020,21(4):479-493.
[16] Camarena C, Aldamiz-Echevarria LJ, Polo B, et al. Update on lysosomal acid lipase deficiency:diagnosis, treatment and patient management. Med Clin (Barc),2017,148(9):429.e1-429,e10.
[17] 张宜琼, 王建设. APOB基因变异致纯合型家族性低β脂蛋白血症1例并文献复习. 中华儿科杂志,2023,61(1):70-75.
[18] Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management.J Inherit Metab Dis,2014,37(3):333-339.
[19] Knottnerus SJG, Bleeker JC, Wüst RCI, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle.Rev Endocr Metab Disord,2018,19(1):93-106.
[20] Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci Rep,2015,36(1):e00281.
[21] Saudubray JM, Martin D, de Lonlay P, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients.J Inherit Metab Dis,1999,22(4):488-502.
[22] Ivin N, Della Torre V, Sanders F, et al. Rhabdomyolysis caused by carnitine palmitoyltransferase 2 deficiency:a case report and systematic review of the literature. J Intensive Care Soc,2020,21(2):165-173.
[23] Carter A, Brackley SM, Gao J, et al. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency:a rare condition that mimics NAFLD. J Hepatol,2019,70(1):142-150.
[24] Saheki T, Moriyama M, Funahashi A, et al. AGC2 (Citrin)deficiency-from recognition of the disease till construction of therapeutic procedures. Biomolecules,2020,10(8):1100.
[25] Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med,2017,19(12):1380-1395.
[26] Ranucci G, Rigoldi M, Cotugno G, et al. Chronic liver involvement in urea cycle disorders.J Inherit Metab Dis,2019,42(6):1118-1127.
[27] Saheki T, Kobayashi K, Iijima M, et al. Metabolic derangements in deficiency of citrin, a liver-type mitochondrial aspartate-glutamate carrier. Hepatol Res,2005,33(2):181-184.
[28] Yeh JN, Jeng YM, Chen HL, et al. Hepatic steatosis and neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) in Taiwanese infants. J Pediatr,2006,148(5):642-646.
[29] Saheki T, Kobayashi K, Iijima M, et al. Adult-onset type II citrullinemia and idiopathic neonatal hepatitis caused by citrin deficiency: involvement of the aspartate glutamate carrier for urea synthesis and maintenance of the urea cycle.Mol Genet Metab,2004,81(Suppl 1):S20-S26.
[30] Okano Y, Ohura T, Sakamoto O, et al. Current treatment for citrin deficiency during NICCD and adaptation/compensation stages: strategy to prevent CTLN2. Mol Genet Metab,2019,127(3):175-183.
[31] Bigot A, Tchan MC, Thoreau B, et al. Liver involvement in urea cycle disorders: a review of the literature.J Inherit Metab Dis,2017,40(6):757-769.
[32] Sakiani S, Kleiner DE, Heller T, et al. Hepaticmanifestations of cystic fibrosis. Clin Liver Dis,2019,23(2):263-277.
[33] Zhang S, Ma Y, Zang X, et al. A case of 17q12 microdeletion syndrome in a MODY5 type diabetes with HNF-1β gene mutation accompanied. Appl Clin Genet,2024,17:125-130.
[34] 王征, 侯维, 郑素军. 肝功能异常的少见原因: 肾囊肿和糖尿病综合征1例. 中华肝脏病杂志,2023,31(7):752-755.
[35] Lopes-Pacheco M. CFTRmodulators: The changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol,2019,10:1662.
[36] Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med,2020,8(1):65-124.
[37] Colombo C, Alicandro G. Liverdisease in cystic fibrosis: illuminating the black box. Hepatology (Baltimore, Md.),2019,69(4):1379-1381.
[38] Ooi CY, Durie PR. Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol,2016,13(3):175-185.
[39] Dana J, Debray D, Beaufrère A, et al. Cystic fibrosis-related liver disease:clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol,2022,76(2):420-434.
[40] Allende DS, Kleiner DE. Fatty liver disease that is neither metabolic nor alcoholic. Hum Pathol,2023,141:212-221.
[41] Bernhard W. Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota. Eur J Nutr,2021,60(4):1737-1759.
[42] Liebe R, Esposito I, Bock HH, et al. Diagnosis and management of secondary causes of steatohepatitis.J Hepatol,2021,74(6):1455-1471.
[43] Hegarty R, Deheragoda M, Fitzpatrick E, et al. Paediatric fatty liver disease (PeFLD):all is not NAFLD-pathophysiological insights and approach to management. J Hepatol,2018,68(6):1286-1299.
[44] 刘晖, 梁晨, 郑素军, 等. 遗传代谢性肝病的病理诊断思路. 中华肝脏病杂志,2022,30(11):1253-1258.

伴有脂肪肝的遗传代谢性肝病诊断策略^*

Inherited metabolic liver diseases that may present with hepatic steatosis: current state of the art

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘莹, 马小宏, 孙长江, 陈爱莲. 超声脂肪分数联合RC/HDL-C比值评估MAFLD患者肝脂肪变性程度价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 513-516.
[2]	彭艳侠, 翟盟. 超声衰减成像联合BMI诊断肥胖儿童代谢功能障碍相关性脂肪性肝病价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 525-528.
[3]	朱晨晨, 庄晓晨, 杨凌菲, 王颖鑫. 基于QUS技术判定非酒精性脂肪性肝病患者肝脂肪变性分级价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 529-532.
[4]	杨鸿, 赖会君, 马磊, 胡明超, 沈晓东, 张金秀. 超声弹性成像参数联合血清肝纤维化指标评估血吸虫病性肝病患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 561-564.
[5]	赖振辉, 蔡银连, 崔东, 文峥. 腹部CT检查参数预测肝硬化门静脉高压症患者并发食管胃底静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 565-568.
[6]	李立方, 王朝阳, 李泽信. 肝脏硬度检测联合FIB-4指数和血清CHI3L1水平预测乙型肝炎肝硬化患者食管静脉曲张效能研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 569-572.
[7]	王冠华, 王萍, 杨金君, 郭娟妮. 超声造影辅助早期诊治细菌性肝脓肿应用价值研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 601-604.
[8]	宇文国琳, 张阿妮, 曾辉, 杨金君, 王冠华. 肝脏炎性假瘤多模态超声特征表现分析^*[J]. 实用肝脏病杂志, 2026, 29(4): 605-608.
[9]	贺婷, 陈旭峰, 周建飞, 郑扬. 腹部超声、CT和MRCP与超声内镜检查诊断胆总管泥沙样结石效能分析^*[J]. 实用肝脏病杂志, 2026, 29(4): 621-624.
[10]	李美涵, 於海天, 郑素军. Gilbert综合征诊断进展^*[J]. 实用肝脏病杂志, 2026, 29(3): 328-331.
[11]	刘建晓, 王燕, 陈世成, 董月稳, 刘向芹, 薛云, 王天赐, 张凯. CT肝细胞外基质体积分数联合血清NOX2和YKL-40水平评估慢性乙型肝炎肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2026, 29(3): 337-340.
[12]	赵迎娣, 陈钰婷, 宗富强. Fibroscan评估非酒精性脂肪性肝病患者肝脏脂肪变性程度应用研究^*[J]. 实用肝脏病杂志, 2026, 29(3): 345-348.
[13]	潘菊花, 陈茜, 王红妹, 季永胜, 蔡政. 清化祛瘀法结合针刺疗法治疗湿热蕴结型代谢相关性脂肪性肝病患者临床疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(3): 349-352.
[14]	曾浩, 李兵, 雷婷, 李顺华, 李孜. FibroScan检测和CT肝脾比值诊断非酒精性脂肪性肝病肝内脂肪分级价值研究^*[J]. 实用肝脏病杂志, 2026, 29(3): 357-360.
[15]	杨茜, 杨冰冰, 王许, 蒋国宁, 聂婧怡, 杨婧妍, 礼广森. 第一阶段射血分数联合LVEF和GLS诊断肝硬化心肌病价值研究[J]. 实用肝脏病杂志, 2026, 29(3): 373-376.